Cognition Therapeutics (CGTX) Competitors $0.32 -0.02 (-5.88%) Closing price 05/21/2025 04:00 PM EasternExtended Trading$0.32 +0.01 (+2.10%) As of 09:04 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CGTX vs. OCX, GNTA, CRVO, PYXS, TELO, EPIX, JSPR, ADAP, IMAB, and STROShould you be buying Cognition Therapeutics stock or one of its competitors? The main competitors of Cognition Therapeutics include OncoCyte (OCX), Genenta Science (GNTA), CervoMed (CRVO), Pyxis Oncology (PYXS), Telomir Pharmaceuticals (TELO), ESSA Pharma (EPIX), Jasper Therapeutics (JSPR), Adaptimmune Therapeutics (ADAP), I-Mab (IMAB), and Sutro Biopharma (STRO). These companies are all part of the "pharmaceutical products" industry. Cognition Therapeutics vs. OncoCyte Genenta Science CervoMed Pyxis Oncology Telomir Pharmaceuticals ESSA Pharma Jasper Therapeutics Adaptimmune Therapeutics I-Mab Sutro Biopharma Cognition Therapeutics (NASDAQ:CGTX) and OncoCyte (NASDAQ:OCX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their community ranking, analyst recommendations, risk, valuation, earnings, profitability, media sentiment, institutional ownership and dividends. Is CGTX or OCX more profitable? Cognition Therapeutics has a net margin of 0.00% compared to OncoCyte's net margin of -6,122.29%. Cognition Therapeutics' return on equity of -150.93% beat OncoCyte's return on equity.Company Net Margins Return on Equity Return on Assets Cognition TherapeuticsN/A -150.93% -100.82% OncoCyte -6,122.29%-269.32%-59.71% Does the MarketBeat Community prefer CGTX or OCX? Cognition Therapeutics received 11 more outperform votes than OncoCyte when rated by MarketBeat users. Likewise, 73.53% of users gave Cognition Therapeutics an outperform vote while only 12.07% of users gave OncoCyte an outperform vote. CompanyUnderperformOutperformCognition TherapeuticsOutperform Votes2573.53% Underperform Votes926.47% OncoCyteOutperform Votes1412.07%Underperform Votes10287.93% Do insiders & institutionals believe in CGTX or OCX? 43.3% of Cognition Therapeutics shares are owned by institutional investors. Comparatively, 55.3% of OncoCyte shares are owned by institutional investors. 20.8% of Cognition Therapeutics shares are owned by company insiders. Comparatively, 1.6% of OncoCyte shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Which has more volatility & risk, CGTX or OCX? Cognition Therapeutics has a beta of 1, suggesting that its share price has a similar volatility profile to the S&P 500.Comparatively, OncoCyte has a beta of 0.95, suggesting that its share price is 5% less volatile than the S&P 500. Do analysts rate CGTX or OCX? Cognition Therapeutics currently has a consensus price target of $6.13, suggesting a potential upside of 1,824.29%. OncoCyte has a consensus price target of $5.42, suggesting a potential upside of 76.44%. Given Cognition Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Cognition Therapeutics is more favorable than OncoCyte.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cognition Therapeutics 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.00OncoCyte 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67 Which has higher earnings and valuation, CGTX or OCX? Cognition Therapeutics has higher earnings, but lower revenue than OncoCyte. OncoCyte is trading at a lower price-to-earnings ratio than Cognition Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCognition TherapeuticsN/AN/A-$25.79M-$0.74-0.43OncoCyte$3.84M22.85-$27.78M-$3.53-0.87 Does the media prefer CGTX or OCX? In the previous week, OncoCyte had 6 more articles in the media than Cognition Therapeutics. MarketBeat recorded 6 mentions for OncoCyte and 0 mentions for Cognition Therapeutics. OncoCyte's average media sentiment score of 0.52 beat Cognition Therapeutics' score of 0.00 indicating that OncoCyte is being referred to more favorably in the news media. Company Overall Sentiment Cognition Therapeutics Neutral OncoCyte Positive SummaryCognition Therapeutics beats OncoCyte on 13 of the 18 factors compared between the two stocks. Get Cognition Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CGTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CGTX vs. The Competition Export to ExcelMetricCognition TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$19.73M$2.93B$5.35B$8.38BDividend YieldN/A1.72%5.22%4.10%P/E Ratio-0.3330.5026.8419.71Price / SalesN/A400.15391.39116.98Price / CashN/A168.6838.2534.62Price / Book0.423.286.794.50Net Income-$25.79M-$72.17M$3.23B$248.18M7 Day Performance-4.56%4.28%4.07%1.14%1 Month Performance-12.46%7.62%12.52%15.20%1 Year Performance-85.98%-28.15%16.83%6.56% Cognition Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CGTXCognition Therapeutics2.55 of 5 stars$0.32-5.9%$6.13+1,824.3%-86.0%$19.73MN/A-0.3320Gap UpOCXOncoCyte2.4132 of 5 stars$2.80+0.4%$4.42+57.7%+8.9%$80.08M$3.84M-0.79120Analyst ForecastGap DownGNTAGenenta Science1.4984 of 5 stars$4.37+2.9%$25.00+471.6%+38.7%$80MN/A0.007Gap UpCRVOCervoMed3.3162 of 5 stars$8.79+0.1%$27.63+214.3%-56.2%$76.41M$7.14M-4.034Gap UpPYXSPyxis Oncology1.4189 of 5 stars$1.23+1.7%$9.00+631.7%-71.3%$76.20M$16.15M-1.1960Trending NewsEarnings ReportAnalyst ForecastAnalyst RevisionTELOTelomir Pharmaceuticals1.7156 of 5 stars$2.54+1.6%$15.00+490.6%-62.6%$75.60MN/A-4.381News CoverageEPIXESSA Pharma2.005 of 5 stars$1.70-0.6%$2.00+17.6%-73.2%$75.46MN/A-2.4650Positive NewsJSPRJasper Therapeutics2.153 of 5 stars$5.02+1.8%$62.22+1,139.5%-79.1%$75.41MN/A-1.0620ADAPAdaptimmune Therapeutics2.7357 of 5 stars$0.29+4.8%$1.52+421.2%-74.5%$74.93M$178.03M-1.32490IMABI-Mab3.1896 of 5 stars$0.91+1.2%$5.50+503.8%-46.4%$74.24M$3.27M0.00380News CoverageSTROSutro Biopharma4.3921 of 5 stars$0.88-3.7%$6.11+596.2%-81.5%$74.18M$66.43M-0.55240News CoverageAnalyst ForecastGap Down Related Companies and Tools Related Companies OncoCyte Competitors Genenta Science Competitors CervoMed Competitors Pyxis Oncology Competitors Telomir Pharmaceuticals Competitors ESSA Pharma Competitors Jasper Therapeutics Competitors Adaptimmune Therapeutics Competitors I-Mab Competitors Sutro Biopharma Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CGTX) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s 2025 Silver Crisis (What It Means for You)Elon Musk is back in the spotlight—this time for fueling a global scramble for silver. Tesla's relentless p...GoldenCrest Metals | SponsoredA new financial chapter Porter Stansberry says what happened last week could become the defining legacy of his financial publishing ca...Porter & Company | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredElon’s backup plan for AIElon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredExclusive Offer: Target 100% Returns NowBrace yourself–this may come as a shock. It turns out that you may not have to wait decades to turn a small...ProsperityPub | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cognition Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cognition Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
